指南
狼疮性肾炎
医学
重症监护医学
肾病科
肾脏疾病
疾病
内科学
病理
作者
Brad H. Rovin,Isabelle Ayoub,Tak Mao Chan,Fei Liu,Juan M. Mejía-Vilet,Ethan M Balk,Craig E. Gordon,Gaelen P Adam,Marcello Tonelli,Michael Cheung,Amy Earley,Jürgen Floege
标识
DOI:10.1016/j.kint.2023.09.001
摘要
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.
科研通智能强力驱动
Strongly Powered by AbleSci AI